RCS - Redx Pharma plc - Redx Presents Encouraging RXC004 Preclinical Data

Redx PharmaAnnouncement

08/04/2022 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220408:nRSH8652Ha&default-theme=true

RNS Number : 8652H  Redx Pharma plc  08 April 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx Presents Encouraging RXC004 Preclinical Data at the AACR Annual Meeting
in Combination with Clinically Relevant Standard of Care Regimens

 

Alderley Park, 8 April 2022, Redx (AIM: REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, announces that its poster at the American Association for
Cancer Research (AACR) Annual Meeting (8-13 April, New Orleans) will be
available for viewing from today. A formal presentation of the poster by the
authors will be made at the conference on 12 April.

 

RXC004, a highly potent and selective, orally active once-daily Porcupine
inhibitor, is being developed as a targeted therapy for Wnt-ligand driven
cancer. It is currently being evaluated as monotherapy in Phase 2
proof-of-concept clinical trials in genetically selected patients with
pancreatic cancer and metastatic colorectal cancer and in unselected patients
with biliary cancer. Additionally, RXC004 is in a Phase 1 combination study
with nivolumab, an anti-PD-1 antibody from which a dose for the combination
arm of the Phase will be selected this year. Data readouts from the Phase 2
studies are expected in 2023.

 

The poster presented at the AACR meeting and entitled 'Pre-clinical efficacy
of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies'
describes preclinical data which demonstrate that RXC004 in combination with
clinically relevant standard of care chemotherapy regimens could lead to
potential benefit, including survival, over chemotherapy alone. The poster
hypothesised that the RXC004-induced downregulation of DNA repair pathway
genes observed in vitro could contribute to the beneficial effect seen in
combination with a PARP inhibitor in vitro as well as the combination effect
observed in vivo with the standard of care chemotherapy agents.

 

Dr Jane Robertson, Chief Medical Officer, Redx Pharma, said: "This preclinical
data further underpins our excitement around the therapeutic potential of
RXC004, and the role of effective Wnt pathway blockade, in tackling a number
of difficult to treat cancers with high unmet need."

 

More information on the contents of the poster

The presented poster, is available on the AACR e-poster website and the
investor section of the Company's website at:
https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/
(https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/)
. It describes how RXC004 was evaluated in a mouse colorectal xenograft model
alone and in combination with both the FOLFIRI* and FOLFIRINOX** treatment
regimens, currently both standard of care chemotherapy in colorectal cancer.
Efficacy was measured by tumour volume and survival endpoint. In addition,
RXC004 was studied in vitro, as monotherapy and in combination with a PARP
inhibitor in genetically selected cell lines with both RSPO-fusion and RNF43
mutation. Combination and monotherapy effects on proliferation and effects on
downstream signalling were investigated.

 

* Folinic acid (FA), fluorouracil (5FU) and irinotecan.

** Folinic acid (FA), fluorouracil (5FU), irinotecan and oxaliplatin.

 For further information, please contact:

 Redx Pharma Plc                                                         T: +44 (0)1625 469 918

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 UK Headquarters

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                             T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                          T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                              T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                          T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About RXC004

RXC004, a highly potent and selective, orally active once-daily Porcupine
inhibitor is being developed as a targeted therapy for Wnt-ligand driven
cancer. Aberrant Wnt signalling contributes directly to tumour growth and
plays an important role in immune evasion, which has also been linked to
resistance to immune-checkpoint inhibitors (ICIs) such as nivolumab. RXC004
has the potential to both directly inhibit the tumour growth and have an
immune-enhancing effect in patients with tumours that have high Wnt-ligand
dependency, such as tumours with mutations in the RNF43 gene and fusions in
the RSPO gene family.

 

Immune checkpoint inhibitors (ICIs) such as anti-PD-1 antibodies have
revolutionised the treatment of cancer, but do not work in all patients. Wnt
pathway activation can enhance the ability of the tumour to evade destruction
by the immune system and has been linked to lack of response to ICIs in these
tumours. Our scientists have demonstrated preclinically that RXC004 can block
activation of the Wnt pathway and restore the ability of the immune system to
fight the tumour. Thus, RXC004 offers potential as a monotherapy or
combination therapy.

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's selective ROCK2 inhibitor product
candidate, RXC007, is in development for idiopathic pulmonary fibrosis and
commenced a Phase 1 clinical trial in June 2021. Encouraging safety and
pharmacokinetic data has been reported, and a Phase 2 clinical program is
confirmed to start in 2022. Redx's third drug candidate, RXC008, a GI-targeted
ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is
currently in pre-IND stage, with Phase 1 clinical studies expected to commence
in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting
fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which
AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)  

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFFRSRITIIF